Impact of Immune Checkpoint Inhibitor on the Survival in Elderly Patients with Non-Small Cell Lung Cancer

Author Info

Minehiko Inomata Kenji Azechi Naoki Takata Kana Hayashi Kotaro Tokui Chihiro Taka Seisuke Okazawa Kenta Kambara Shingo Imanishi Toshiro Miwa Ryuji Hayashi Shoko Matsui Kazuyuki Tobe

Corresponding Author

Minehiko Inomata
First Department of Internal Medicine, Toyama University Hospital, Japan

A B S T R A C T

Purpose: We analysed the relationship between a history of immune checkpoint inhibitor (ICI) and overall survival in elderly patients with non-small cell lung cancer (NSCLC). Methods: We conducted a retrospective analysis of the data of patients with NSCLC aged ≥70-year-old who had received systemic anticancer therapy between 2015 and 2019. Results: The analysis included the data of a total of 63 patients. Multivariate analysis revealed a significant association between a history of treatment with ICI and the overall survival. A significant interaction was also observed between a history of treatment with an ICI and the tumor histology. Conclusion: A significant association between history of ICI therapy and the overall survival was detected in elderly NSCLC patients aged ≥70-year-old in a clinical practice setting. Our results also suggested that the impact of ICI therapy on the survival differed depending on the tumor histology.

Article Info

Article Type

Research Article

Publication history

Received: Sat 05, Dec 2020
Accepted: Mon 21, Dec 2020
Published: Thu 31, Dec 2020

Copyright

© 2023 Minehiko Inomata. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2020.12.04